Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Interest & Investment Income (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Interest & Investment Income for 13 consecutive years, with $4.2 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Interest & Investment Income fell 21.1% year-over-year to $4.2 million, compared with a TTM value of $16.9 million through Mar 2025, down 24.36%, and an annual FY2024 reading of $18.0 million, down 21.28% over the prior year.
  • Interest & Investment Income was $4.2 million for Q1 2025 at Tandem Diabetes Care, down from $4.5 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $5.9 million in Q1 2023 and bottomed at -$47000.0 in Q4 2021.
  • Average Interest & Investment Income over 5 years is $3.0 million, with a median of $3.1 million recorded in 2022.
  • The sharpest move saw Interest & Investment Income plummeted 114.2% in 2021, then surged 6687.23% in 2022.
  • Year by year, Interest & Investment Income stood at -$47000.0 in 2021, then soared by 6687.23% to $3.1 million in 2022, then skyrocketed by 79.36% to $5.6 million in 2023, then decreased by 18.76% to $4.5 million in 2024, then decreased by 7.05% to $4.2 million in 2025.
  • Business Quant data shows Interest & Investment Income for TNDM at $4.2 million in Q1 2025, $4.5 million in Q4 2024, and $5.3 million in Q3 2024.